Acquired generalized lipodystrophy

Summary

Acquired generalized lipodystrophy (MONDO:0019193) is a disease. A subtype of acquired lipodystrophy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 28

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000	1	Europe	Validated

Signs & symptoms

Clinical features (HPO)

28 HPO clinical features (Orphanet curated; top 28 by frequency):

HPO ID	Term	Frequency
HP:0009064	Generalized lipodystrophy	Obligate (100%)
HP:0000842	Hyperinsulinemia	Very frequent (80-99%)
HP:0000855	Insulin resistance	Very frequent (80-99%)
HP:0000831	Insulin-resistant diabetes mellitus	Frequent (30-79%)
HP:0001397	Hepatic steatosis	Frequent (30-79%)
HP:0001638	Cardiomyopathy	Frequent (30-79%)
HP:0002960	Autoimmunity	Frequent (30-79%)
HP:0003119	Abnormal circulating lipid concentration	Frequent (30-79%)
HP:0003707	Calf muscle pseudohypertrophy	Frequent (30-79%)
HP:0005328	Progeroid facial appearance	Frequent (30-79%)
HP:0011025	Abnormality of cardiovascular system physiology	Frequent (30-79%)
HP:0000093	Proteinuria	Occasional (5-29%)
HP:0000147	Polycystic ovaries	Occasional (5-29%)
HP:0000822	Hypertension	Occasional (5-29%)
HP:0000956	Acanthosis nigricans	Occasional (5-29%)
HP:0001394	Cirrhosis	Occasional (5-29%)
HP:0001735	Acute pancreatitis	Occasional (5-29%)
HP:0002155	Hypertriglyceridemia	Occasional (5-29%)
HP:0002230	Generalized hirsutism	Occasional (5-29%)
HP:0002240	Hepatomegaly	Occasional (5-29%)
HP:0003198	Myopathy	Occasional (5-29%)
HP:0005339	Abnormality of complement system	Occasional (5-29%)
HP:0005616	Accelerated skeletal maturation	Occasional (5-29%)
HP:0007440	Generalized hyperpigmentation	Occasional (5-29%)
HP:0012490	Panniculitis	Occasional (5-29%)
HP:0002665	Lymphoma	Very rare (<1-4%)
HP:0009592	Astrocytoma	Very rare (<1-4%)
HP:0012064	Unicameral bone cyst	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	acquired generalized lipodystrophy
Mondo ID	MONDO:0019193
Orphanet	79086
DOID	DOID:0080300
NCIT	C131089
SNOMED CT	86907008
UMLS	C0271693
MedGen	543499
GARD	0012603
Is cancer (heuristic)	no

Also known as: acquired generalized lipodystrophy · acquired lipoatrophic diabetes · Lawrence syndrome · Lawrence-Seip syndrome

Disease family

This is a subtype of acquired lipodystrophy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › acquired metabolic disease › acquired lipodystrophy › acquired generalized lipodystrophy

Related subtypes (1): acquired partial lipodystrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.